Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

First Posted Date: 2016-08-26

Last Posted Date: 2024-10-10

Lead Sponsor: Goethe University

Target Recruit Count: 1000

Registration Number: NCT02881086

Locations: 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Phase 1

Conditions: Lymphoblastic Leukemia, Acute
Lymphoblastic Leukemia, Acute, Childhood
ALL, Childhood

Interventions: Drug: Marqibo

First Posted Date: 2016-08-26

Last Posted Date: 2020-04-17

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 36

Registration Number: NCT02879643

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States

and more 32 locations

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Phase 2

Recruiting

Conditions: Retinoblastoma

Interventions: Radiation: Orbital irradiation
Other: Observation
Drug: Etoposide
Drug: Vincristine
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Cytapheresis
Procedure: Peripheral bood stem cell transplantation

First Posted Date: 2016-08-17

Last Posted Date: 2024-05-31

Lead Sponsor: Institut Curie

Target Recruit Count: 185

Registration Number: NCT02870907

Locations: 🇫🇷
Chr Felix Guyon, Saint-Denis, La Réunion, France
🇫🇷
Hopital Nord Chu Amiens, Amiens, France
🇫🇷
Chu Angers, Angers, France

and more 24 locations

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase 4

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Thalidomide
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Cisplatin
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2016-08-08

Last Posted Date: 2019-06-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT02858804

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2

Terminated

Conditions: Transformed Lymphoma / DLBCL
Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3b

Interventions: Drug: denintuzumab mafodotin
Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2016-08-04

Last Posted Date: 2019-03-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 24

Registration Number: NCT02855359

Locations: 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸
Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 32 locations

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

First Posted Date: 2016-07-11

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT02828358

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 170 locations